RxDoctor Payments Data

Yuerong Bayer, NP

Adult Health · Cleveland, OHNPI 1184134561

Payments from drug & device makers

$6,623in general payments, 2019–2025

Across 363 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$848
  • AstraZeneca$778
  • Amgen$552
  • Boehringer Ingelheim$336
  • Merck$264
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$6,56899%
  • Education$551%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,623 in reported general payments places this provider in the 90th percentile of 1,184 adult health providers in Ohio.

See all adult health providers in Ohio

Medicare billing

Part B allowed, 2024
$77,689
Medicare patients
273
Services billed
1,277

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$38,955
MounjaroTirzepatide26$32,598
JardianceEmpagliflozin52$25,627
ProliaDenosumab12$22,384
EliquisApixaban58$18,742
Aimovig AutoinjectorErenumab-Aooe16$12,603
MyrbetriqMirabegron29$9,998
LinzessLinaclotide14$7,927
Repatha SyringeEvolocumab17$7,781
EntrestoSacubitril/Valsartan17$5,818
GemtesaVibegron15$3,659
Fluticasone-SalmeterolFluticasone Propion/Salmeterol16$2,420
Sucralfate13$2,108
Fentanyl20$2,080
Lacosamide41$1,884

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$848$38,95532 claims
Lilly USA, LLCMounjaro$125$32,59826 claims
Boehringer IngelheimJardiance$336$25,62752 claims
AmgenProlia$552$22,38412 claims
PfizerEliquis$213$18,74258 claims
Astellas Pharma US IncMyrbetriq$16$9,99829 claims
AbbVieLinzess$1,737$7,92714 claims
NovartisEntresto$108$5,81817 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$14$97576 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,184 adult health providers in Ohio.

Other adult health in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →